Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

combigene.com

Founded Year

2008

Stage

IPO | IPO

Total Raised

$4.27M

Date of IPO

12/19/2018

Market Cap

0.15B

About CombiGene

CombiGene is developing treatment methods for epilepsy patients. Combining advances in neuroscience and modern genetic engineering, CombiGene developed a treatment method that, in preclinical studies, proved to prevent epilepsy cases. The company is focusing on further developing this treatment method to accommodate epilepsy patients.

CombiGene Headquarters Location

Scheelevagen 2 Medicon Village

Lund, 223-81,

Sweden

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CombiGene

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CombiGene is included in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

CombiGene Patents

CombiGene has filed 2 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Neurological disorders
  • Rare diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/10/2017

7/27/2021

Transcription factors, Rare diseases, Neurological disorders, Syndromes, Molecular biology

Grant

Application Date

2/10/2017

Grant Date

7/27/2021

Title

Related Topics

Transcription factors, Rare diseases, Neurological disorders, Syndromes, Molecular biology

Status

Grant

Latest CombiGene News

Spark signs gene therapy licensing deal valued at up to $328.5M

Oct 14, 2021

Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, and CombiGene AB (‘CombiGene’) today announced the signing of an exclusive collaboration and licensing agreement for CombiGene’s CG01 project, an investigational gene therapy which aims to treat drug resistant focal epilepsy. The agreement provides Spark with the exclusive, worldwide license to develop, manufacture and commercialize CG01. CombiGene will continue to execute certain aspects of the preclinical program in collaboration with Spark. The post Spark signs gene therapy licensing deal valued at up to $328.5M appeared first on BioBuzz.

CombiGene Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CombiGene Rank

  • When was CombiGene founded?

    CombiGene was founded in 2008.

  • Where is CombiGene's headquarters?

    CombiGene's headquarters is located at Scheelevagen 2, Lund.

  • What is CombiGene's latest funding round?

    CombiGene's latest funding round is IPO.

  • How much did CombiGene raise?

    CombiGene raised a total of $4.27M.

  • Who are the investors of CombiGene?

    Investors of CombiGene include Horizon 2020.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.